CCL22 Recruits CD4-positive CD25-positive Regulatory T Cells into Malignant Pleural Effusion
Purpose: The aim of this study was to explore the presence of the chemokines CCL22 and CCL17 in malignant pleural effusion, and the chemoattractant activity of these chemokines on CD4-positive CD25-positive Foxp3-positive regulatory T cells infiltrating into the pleural space. Experimental Design: T...
Saved in:
Published in | Clinical cancer research Vol. 15; no. 7; pp. 2231 - 2237 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Philadelphia, PA
American Association for Cancer Research
01.04.2009
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Purpose: The aim of this study was to explore the presence of the chemokines CCL22 and CCL17 in malignant pleural effusion, and the
chemoattractant activity of these chemokines on CD4-positive CD25-positive Foxp3-positive regulatory T cells infiltrating
into the pleural space.
Experimental Design: The concentrations of CCL22 and CCL17 in both pleural effusions and sera from 33 patients with lung cancer were determined.
Flow cytometry was done to determine T lymphocyte subsets in cell pellets of pleural effusion. Pleural cells were analyzed
for the expression of CCL22 and CCL17. The chemoattractant activity of CCL22 for regulatory T cells in vitro and in vivo was also observed.
Results: The concentration of CCL22 in malignant pleural effusion was significantly higher than that in the corresponding serum. Pleural
fluid from lung cancer patients was chemotactic for regulatory T cells, and this activity was partly blocked by an anti-CCL22,
but not by an anti-CCL17 antibody. Intrapleural administration of CCL22 of patients produced a marked progressive influx of
regulatory T cells into pleural space.
Conclusions: Compared with serum, CCL22 seemed to be increased in malignant pleural effusion, and could directly induce regulatory T cell
infiltration into the pleural space in patients with malignant effusion. |
---|---|
AbstractList | Purpose: The aim of this study was to explore the presence of the chemokines CCL22 and CCL17 in malignant pleural effusion, and the chemoattractant activity of these chemokines on CD4-positive CD25-positive Foxp3-positive regulatory T cells infiltrating into the pleural space.
Experimental Design: The concentrations of CCL22 and CCL17 in both pleural effusions and sera from 33 patients with lung cancer were determined. Flow cytometry was done to determine T lymphocyte subsets in cell pellets of pleural effusion. Pleural cells were analyzed for the expression of CCL22 and CCL17. The chemoattractant activity of CCL22 for regulatory T cells in vitro and in vivo was also observed.
Results: The concentration of CCL22 in malignant pleural effusion was significantly higher than that in the corresponding serum. Pleural fluid from lung cancer patients was chemotactic for regulatory T cells, and this activity was partly blocked by an anti-CCL22, but not by an anti-CCL17 antibody. Intrapleural administration of CCL22 of patients produced a marked progressive influx of regulatory T cells into pleural space.
Conclusions: Compared with serum, CCL22 seemed to be increased in malignant pleural effusion, and could directly induce regulatory T cell infiltration into the pleural space in patients with malignant effusion. The aim of this study was to explore the presence of the chemokines CCL22 and CCL17 in malignant pleural effusion, and the chemoattractant activity of these chemokines on CD4-positive CD25-positive Foxp3-positive regulatory T cells infiltrating into the pleural space. The concentrations of CCL22 and CCL17 in both pleural effusions and sera from 33 patients with lung cancer were determined. Flow cytometry was done to determine T lymphocyte subsets in cell pellets of pleural effusion. Pleural cells were analyzed for the expression of CCL22 and CCL17. The chemoattractant activity of CCL22 for regulatory T cells in vitro and in vivo was also observed. The concentration of CCL22 in malignant pleural effusion was significantly higher than that in the corresponding serum. Pleural fluid from lung cancer patients was chemotactic for regulatory T cells, and this activity was partly blocked by an anti-CCL22, but not by an anti-CCL17 antibody. Intrapleural administration of CCL22 of patients produced a marked progressive influx of regulatory T cells into pleural space. Compared with serum, CCL22 seemed to be increased in malignant pleural effusion, and could directly induce regulatory T cell infiltration into the pleural space in patients with malignant effusion. The aim of this study was to explore the presence of the chemokines CCL22 and CCL17 in malignant pleural effusion, and the chemoattractant activity of these chemokines on CD4-positive CD25-positive Foxp3-positive regulatory T cells infiltrating into the pleural space.PURPOSEThe aim of this study was to explore the presence of the chemokines CCL22 and CCL17 in malignant pleural effusion, and the chemoattractant activity of these chemokines on CD4-positive CD25-positive Foxp3-positive regulatory T cells infiltrating into the pleural space.The concentrations of CCL22 and CCL17 in both pleural effusions and sera from 33 patients with lung cancer were determined. Flow cytometry was done to determine T lymphocyte subsets in cell pellets of pleural effusion. Pleural cells were analyzed for the expression of CCL22 and CCL17. The chemoattractant activity of CCL22 for regulatory T cells in vitro and in vivo was also observed.EXPERIMENTAL DESIGNThe concentrations of CCL22 and CCL17 in both pleural effusions and sera from 33 patients with lung cancer were determined. Flow cytometry was done to determine T lymphocyte subsets in cell pellets of pleural effusion. Pleural cells were analyzed for the expression of CCL22 and CCL17. The chemoattractant activity of CCL22 for regulatory T cells in vitro and in vivo was also observed.The concentration of CCL22 in malignant pleural effusion was significantly higher than that in the corresponding serum. Pleural fluid from lung cancer patients was chemotactic for regulatory T cells, and this activity was partly blocked by an anti-CCL22, but not by an anti-CCL17 antibody. Intrapleural administration of CCL22 of patients produced a marked progressive influx of regulatory T cells into pleural space.RESULTSThe concentration of CCL22 in malignant pleural effusion was significantly higher than that in the corresponding serum. Pleural fluid from lung cancer patients was chemotactic for regulatory T cells, and this activity was partly blocked by an anti-CCL22, but not by an anti-CCL17 antibody. Intrapleural administration of CCL22 of patients produced a marked progressive influx of regulatory T cells into pleural space.Compared with serum, CCL22 seemed to be increased in malignant pleural effusion, and could directly induce regulatory T cell infiltration into the pleural space in patients with malignant effusion.CONCLUSIONSCompared with serum, CCL22 seemed to be increased in malignant pleural effusion, and could directly induce regulatory T cell infiltration into the pleural space in patients with malignant effusion. Purpose: The aim of this study was to explore the presence of the chemokines CCL22 and CCL17 in malignant pleural effusion, and the chemoattractant activity of these chemokines on CD4-positive CD25-positive Foxp3-positive regulatory T cells infiltrating into the pleural space. Experimental Design: The concentrations of CCL22 and CCL17 in both pleural effusions and sera from 33 patients with lung cancer were determined. Flow cytometry was done to determine T lymphocyte subsets in cell pellets of pleural effusion. Pleural cells were analyzed for the expression of CCL22 and CCL17. The chemoattractant activity of CCL22 for regulatory T cells in vitro and in vivo was also observed. Results: The concentration of CCL22 in malignant pleural effusion was significantly higher than that in the corresponding serum. Pleural fluid from lung cancer patients was chemotactic for regulatory T cells, and this activity was partly blocked by an anti-CCL22, but not by an anti-CCL17 antibody. Intrapleural administration of CCL22 of patients produced a marked progressive influx of regulatory T cells into pleural space. Conclusions: Compared with serum, CCL22 seemed to be increased in malignant pleural effusion, and could directly induce regulatory T cell infiltration into the pleural space in patients with malignant effusion. |
Author | Xue-Jun Qin Zhi-Jian Ye Jing-Min Deng Jing Jiang Huan-Zhong Shi Qiu-Li Liang |
Author_xml | – sequence: 1 givenname: Xue-Jun surname: Qin fullname: Qin, Xue-Jun – sequence: 2 givenname: Huan-Zhong surname: Shi fullname: Shi, Huan-Zhong – sequence: 3 givenname: Jing-Min surname: Deng fullname: Deng, Jing-Min – sequence: 4 givenname: Qiu-Li surname: Liang fullname: Liang, Qiu-Li – sequence: 5 givenname: Jing surname: Jiang fullname: Jiang, Jing – sequence: 6 givenname: Zhi-Jian surname: Ye fullname: Ye, Zhi-Jian |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21657140$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/19318474$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkV1rFDEUhoNU7If-BGVuFG-m5uRjksErGWsrrChLvRNCNnNmN5Kd2SYZpf_eLLut4I1XyYHnDe_Jc05OxmlEQl4CvQSQ-h1QpWsqOLvsumVNdc0aAU_IGUipas4aeVLuD8wpOU_pJ6UggIpn5BRaDloocUZ-dN2CsWqJLs4-p6r7KOrdlHz2v7AMTP6dlrieg81TvK9uqw5DSJUf81R9scGvRzvm6lvAOdpQXQ3DnPw0PidPBxsSvjieF-T7p6vb7qZefL3-3H1Y1E6AyvXQWmUlxUbYXjq5Qs2k1LQXODDNqVIguBhEy22rSm3JHKBaadlCL2jbc35B3hze3cXpbsaUzdYnVxraEac5mUYB1RqggK-O4LzaYm920W9tvDcP_1GA10fAJmfDEO3ofHrkGDSytKGFe3_gXJxSijgY57PNZeccrQ8GqNlbMnsDZm_AFEuGarO3VNLyn_Rjkf_k3h5yG7_e_PYRjSv9MEZMaKPbGJBGGcY48D9CZ6Bq |
CODEN | CCREF4 |
CitedBy_id | crossref_primary_10_1164_rccm_201207_1307OC crossref_primary_10_4049_jimmunol_0903846 crossref_primary_10_1089_mab_2015_0039 crossref_primary_10_3389_fimmu_2019_02453 crossref_primary_10_1080_15563650_2021_1945081 crossref_primary_10_3389_fcell_2022_816927 crossref_primary_10_1038_s41598_024_75750_1 crossref_primary_10_1080_2162402X_2015_1030561 crossref_primary_10_1158_0008_5472_CAN_11_0952 crossref_primary_10_1186_1471_2407_13_324 crossref_primary_10_1164_rccm_201203_0465PP crossref_primary_10_1186_s12935_024_03211_w crossref_primary_10_1016_j_ejca_2011_03_026 crossref_primary_10_1371_journal_pone_0076379 crossref_primary_10_3892_or_2014_3576 crossref_primary_10_4110_in_2009_9_6_209 crossref_primary_10_1158_1535_7163_MCT_14_0448 crossref_primary_10_1159_000362332 crossref_primary_10_1164_rccm_201401_0140ED crossref_primary_10_1111_j_1365_2559_2011_04040_x crossref_primary_10_1007_s00262_011_1059_6 crossref_primary_10_4049_jimmunol_1001728 crossref_primary_10_1016_j_jconrel_2015_08_014 crossref_primary_10_1159_000447687 crossref_primary_10_3109_08830185_2010_508854 crossref_primary_10_1016_j_imbio_2014_11_007 crossref_primary_10_1097_IGC_0b013e3182289ab1 crossref_primary_10_1002_hed_21581 crossref_primary_10_1371_journal_pone_0251233 crossref_primary_10_3390_ijms21218412 crossref_primary_10_3389_fimmu_2023_1161375 crossref_primary_10_4049_jimmunol_1400567 crossref_primary_10_1097_MOT_0000000000000130 crossref_primary_10_1016_j_intimp_2023_111332 crossref_primary_10_1111_j_1440_1843_2010_01890_x crossref_primary_10_1039_D1BM00971K crossref_primary_10_1038_s41420_023_01312_5 crossref_primary_10_1080_2162402X_2018_1554969 crossref_primary_10_1016_j_canlet_2020_12_016 crossref_primary_10_1371_journal_pone_0040450 crossref_primary_10_1002_ctm2_1356 crossref_primary_10_1038_s41598_018_35840_3 crossref_primary_10_3389_fonc_2021_672747 crossref_primary_10_1155_2011_865684 crossref_primary_10_1586_era_12_153 crossref_primary_10_1172_JCI43048 crossref_primary_10_1038_onc_2016_458 crossref_primary_10_1111_imr_12761 crossref_primary_10_1016_j_jss_2016_11_067 crossref_primary_10_3389_fimmu_2021_760683 crossref_primary_10_1016_j_pharmthera_2009_12_003 crossref_primary_10_1016_j_yexcr_2022_113212 crossref_primary_10_1038_s42003_022_04356_y crossref_primary_10_1016_j_canlet_2012_07_013 crossref_primary_10_1007_s11596_013_1066_2 crossref_primary_10_1111_crj_12351 crossref_primary_10_4161_onci_26836 crossref_primary_10_1038_s41417_023_00678_z crossref_primary_10_1155_2014_730380 crossref_primary_10_1186_s12967_015_0618_6 crossref_primary_10_1186_1465_9921_12_77 crossref_primary_10_1158_2326_6066_CIR_13_0028 crossref_primary_10_1158_0008_5472_CAN_11_0573 crossref_primary_10_5507_bp_2016_062 crossref_primary_10_1016_j_it_2014_07_004 crossref_primary_10_3390_ijms21165647 crossref_primary_10_1016_j_canlet_2019_03_040 |
Cites_doi | 10.4049/jimmunol.172.9.5213 10.1038/nm1093 10.1158/1078-0432.CCR-04-0371 10.1016/j.clim.2006.10.014 10.1084/jem.194.6.847 10.1038/ni1180 10.1002/ijc.23392 10.1093/intimm/dxm014 10.1038/nri821 10.1182/blood-2005-02-0642 10.1183/09031936.93.01040337 10.1093/jnci/djm064 10.1164/rccm.200504-588OC 10.1158/1078-0432.CCR-03-0239 10.1182/blood-2006-02-002774 10.1016/j.humimm.2005.11.005 10.1164/ajrccm.162.5.ats8-00 10.1378/chest.06-1757 10.1097/01.mcp.0000166490.92659.17 10.1378/chest.103.6.1732 10.4049/jimmunol.177.7.4488 10.1056/NEJMcp010731 10.1097/00029330-200804010-00001 10.1158/0008-5472.CAN-06-0261 10.4049/jimmunol.168.9.4272 10.1183/09031936.05.00090804 |
ContentType | Journal Article |
Copyright | 2009 INIST-CNRS |
Copyright_xml | – notice: 2009 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1158/1078-0432.CCR-08-2641 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1557-3265 |
EndPage | 2237 |
ExternalDocumentID | 19318474 21657140 10_1158_1078_0432_CCR_08_2641 15_7_2231 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | - 29B 2WC 34G 39C 3O- 4H- 53G 55 5GY 5RE 5VS AAPBV ABFLS ABOCM ACIWK ACPRK ADACO ADBBV ADBIT AENEX AETEA AFFNX AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL C1A CS3 DIK DU5 E3Z EBS EJD F5P FH7 FRP GX1 H13 H~9 IH2 KQ8 L7B LSO MVM O0- OHT OK1 P0W P2P RCR RHF RHI RNS SJN UDS VH1 W2D WOQ X7M XFK XJT ZA5 ZCG --- .55 18M 2FS 6J9 AAFWJ AAJMC AAYXX ACGFO ACSVP ADCOW AFHIN AFOSN AFUMD AI. BR6 BTFSW CITATION QTD TR2 W8F YKV .GJ 1CY ADNWM IQODW J5H WHG ZGI CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c417t-f9a7a50e64ad5c5be825580d4ef2830771434f493a9718452c1e7b8591d409d33 |
ISSN | 1078-0432 |
IngestDate | Fri Jul 11 00:57:35 EDT 2025 Thu Apr 03 06:57:25 EDT 2025 Mon Jul 21 09:13:39 EDT 2025 Tue Jul 01 03:06:20 EDT 2025 Thu Apr 24 23:03:38 EDT 2025 Fri Jan 15 19:22:03 EST 2021 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Keywords | CD4 T lymphocyte T-Lymphocyte Pleural disease Malignant tumor Malignant pleural effusion Regulatory cell Cancer |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c417t-f9a7a50e64ad5c5be825580d4ef2830771434f493a9718452c1e7b8591d409d33 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://aacrjournals.org/clincancerres/article-pdf/15/7/2231/1987917/2231.pdf |
PMID | 19318474 |
PQID | 67108811 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_67108811 pubmed_primary_19318474 pascalfrancis_primary_21657140 crossref_citationtrail_10_1158_1078_0432_CCR_08_2641 crossref_primary_10_1158_1078_0432_CCR_08_2641 highwire_cancerresearch_15_7_2231 |
ProviderPackageCode | RHF RHI CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2009-04-01 |
PublicationDateYYYYMMDD | 2009-04-01 |
PublicationDate_xml | – month: 04 year: 2009 text: 2009-04-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Philadelphia, PA |
PublicationPlace_xml | – name: Philadelphia, PA – name: United States |
PublicationTitle | Clinical cancer research |
PublicationTitleAlternate | Clin Cancer Res |
PublicationYear | 2009 |
Publisher | American Association for Cancer Research |
Publisher_xml | – name: American Association for Cancer Research |
References | 2022061022335836200_B17 2022061022335836200_B18 2022061022335836200_B15 2022061022335836200_B16 2022061022335836200_B19 2022061022335836200_B10 2022061022335836200_B1 2022061022335836200_B13 2022061022335836200_B14 2022061022335836200_B3 2022061022335836200_B11 2022061022335836200_B2 2022061022335836200_B12 2022061022335836200_B5 2022061022335836200_B4 2022061022335836200_B7 2022061022335836200_B6 2022061022335836200_B9 2022061022335836200_B8 2022061022335836200_B28 2022061022335836200_B26 2022061022335836200_B27 2022061022335836200_B20 2022061022335836200_B21 2022061022335836200_B24 2022061022335836200_B25 2022061022335836200_B22 2022061022335836200_B23 |
References_xml | – ident: 2022061022335836200_B18 doi: 10.4049/jimmunol.172.9.5213 – ident: 2022061022335836200_B22 doi: 10.1038/nm1093 – ident: 2022061022335836200_B28 doi: 10.1158/1078-0432.CCR-04-0371 – ident: 2022061022335836200_B19 doi: 10.1016/j.clim.2006.10.014 – ident: 2022061022335836200_B25 doi: 10.1084/jem.194.6.847 – ident: 2022061022335836200_B27 – ident: 2022061022335836200_B5 doi: 10.1038/ni1180 – ident: 2022061022335836200_B11 doi: 10.1002/ijc.23392 – ident: 2022061022335836200_B20 doi: 10.1093/intimm/dxm014 – ident: 2022061022335836200_B4 doi: 10.1038/nri821 – ident: 2022061022335836200_B7 – ident: 2022061022335836200_B13 doi: 10.1182/blood-2005-02-0642 – ident: 2022061022335836200_B16 doi: 10.1183/09031936.93.01040337 – ident: 2022061022335836200_B21 doi: 10.1093/jnci/djm064 – ident: 2022061022335836200_B10 doi: 10.1164/rccm.200504-588OC – ident: 2022061022335836200_B12 doi: 10.1158/1078-0432.CCR-03-0239 – ident: 2022061022335836200_B6 doi: 10.1182/blood-2006-02-002774 – ident: 2022061022335836200_B9 doi: 10.1016/j.humimm.2005.11.005 – ident: 2022061022335836200_B14 doi: 10.1164/ajrccm.162.5.ats8-00 – ident: 2022061022335836200_B15 doi: 10.1378/chest.06-1757 – ident: 2022061022335836200_B2 doi: 10.1097/01.mcp.0000166490.92659.17 – ident: 2022061022335836200_B17 doi: 10.1378/chest.103.6.1732 – ident: 2022061022335836200_B26 doi: 10.4049/jimmunol.177.7.4488 – ident: 2022061022335836200_B1 doi: 10.1056/NEJMcp010731 – ident: 2022061022335836200_B3 doi: 10.1097/00029330-200804010-00001 – ident: 2022061022335836200_B24 doi: 10.1158/0008-5472.CAN-06-0261 – ident: 2022061022335836200_B8 doi: 10.4049/jimmunol.168.9.4272 – ident: 2022061022335836200_B23 doi: 10.1183/09031936.05.00090804 |
SSID | ssj0014104 |
Score | 2.2333102 |
Snippet | Purpose: The aim of this study was to explore the presence of the chemokines CCL22 and CCL17 in malignant pleural effusion, and the
chemoattractant activity of... Purpose: The aim of this study was to explore the presence of the chemokines CCL22 and CCL17 in malignant pleural effusion, and the chemoattractant activity of... The aim of this study was to explore the presence of the chemokines CCL22 and CCL17 in malignant pleural effusion, and the chemoattractant activity of these... |
SourceID | proquest pubmed pascalfrancis crossref highwire |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 2231 |
SubjectTerms | Adult Aged Aged, 80 and over Antineoplastic agents Biological and medical sciences Chemokine CCL17 - analysis Chemokine CCL22 - metabolism Chemokine CCL22 - pharmacology Chemokine CCL22 - physiology Chemotaxis Humans Interleukin-2 Receptor alpha Subunit - analysis lung cancer malignant pleural effusion Medical sciences Middle Aged Pharmacology. Drug treatments Pleural Effusion, Malignant - immunology regulatory T cells T-Lymphocytes, Regulatory - immunology |
Title | CCL22 Recruits CD4-positive CD25-positive Regulatory T Cells into Malignant Pleural Effusion |
URI | http://clincancerres.aacrjournals.org/content/15/7/2231.abstract https://www.ncbi.nlm.nih.gov/pubmed/19318474 https://www.proquest.com/docview/67108811 |
Volume | 15 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKkBAvaHyXwTASb1VK4thN8oiyoTFaBKWTKoRk5cPZKpVsWhse-Mf497iznS8YYvASNVGdnvr7-Xx3Pt8R8hIcnNDzsshRLGAOT3If5pwXOZPcVV4eJjws0FGcvZ8cnfDjpVgOBj86WUvVNh1n3688V_I_qMIzwBVPyf4Dss1L4QF8BnzhCgjD9VoYx_GUMW35VRj_jw-4Y5Kwvim4YaK9m5uW87ihvhjFar3GNCwwO2dghp9iLszow1rpChyHRVFtarDqEgb18ckMOXI5shWCmkjyslLOcVWOPq7KliZJ6Xw-w05Gn85WTZ4OLJTObFWCmrMrJsZcV5UzXY2mQNTTXhAi6uSutHn_oJA6nNJpkrERa94VyyhaFyv7chvbVFb5ClB4zPSOaLSz6LAw6KpaZpaP39cAEepwhP2BcRzPMQgMll_v-wDlxVdNDLBhwc81zYL6Fbl_WSmb_EVPyECiADfITQb-CbbOOHj7rtm-4p7uW9nIYI-OgWSvrpRLl641QvTto7pmNabsJhsAujDtVv7sD2m7aLFL7liHhr427LxLBqq8R27NbMrGffJFk5TWJKVdktIeSWlLUrqgmqQUSUobklJLUlqT9AE5eXO4iI8c29LDybgXbJ0iSoJEuGoCWkFkIlUhuLShm3NVYCW6IADznRc88pMIjCYuWOapIMUaizl3o9z3H5Kd8rxUjwn1fZV4XClYsV2eF3nqgy2mchjHeCFYOiS8_iNlZuvdY9uVtdR-rwglQiERCglQSDeUCMWQjJthF6bgy98GvKhRkmYW1pNQNjQZkv0efM2bmTcRWDJzSJ7XeErQ77hpl5TqvNrICbgAIajTIXlkYG6lsox5cg0B9sjtdto-JTvby0o9A2t6m-5r5v4Ef9HBrA |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CCL22+Recruits+CD4-positive+CD25-positive+Regulatory+T+Cells+into+Malignant+Pleural+Effusion&rft.jtitle=Clinical+cancer+research&rft.au=Xue-Jun+Qin&rft.au=Huan-Zhong+Shi&rft.au=Jing-Min+Deng&rft.au=Qiu-Li+Liang&rft.date=2009-04-01&rft.pub=American+Association+for+Cancer+Research&rft.issn=1078-0432&rft.eissn=1557-3265&rft.volume=15&rft.issue=7&rft.spage=2231&rft_id=info:doi/10.1158%2F1078-0432.CCR-08-2641&rft_id=info%3Apmid%2F19318474&rft.externalDBID=n%2Fa&rft.externalDocID=15_7_2231 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon |